Brooks Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute

Rhea-AI Summary

Brooks Automation (Nasdaq:BRKS) announced that its genomics division, GENEWIZ, has secured one of six IDIQ contracts from the National Cancer Institute (NCI). This contract will enable GENEWIZ to provide whole exome sequencing for NCI’s Center for Cancer Genomics over the next three years. The collaboration aims to generate data to advance cancer research and improve patient outcomes. The award reflects GENEWIZ's strong reputation in the cancer research community and its commitment to supporting vital genomic research initiatives.

Positive

• Awarded a significant contract by NCI for whole exome sequencing over three years.
• Strengthens GENEWIZ's reputation in the cancer research space.
• Supports critical cancer research initiatives that may enhance treatment outcomes.

Negative

• None.

CHELMSFORD, Mass., Jan. 12, 2021 /PRNewswire/ -- Brooks Automation, Inc. (Nasdaq:BRKS)  announced today that GENEWIZ, the Company's genomics analysis business, has been awarded one of six  Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI). The NCI, the nation's leader in cancer research and part of the National Institutes of Health (NIH), chose GENEWIZ to provide whole exome sequencing to new research projects at its Center for Cancer Genomics for a period of three years.

"This contract for Brooks to provide whole exome sequencing to the National Cancer Institute demonstrates the outstanding reputation of GENEWIZ in the cancer research community," commented Steve Schwartz, president and CEO of Brooks Automation. "We are proud that GENEWIZ's expertise in gene sequencing is an enabling factor for the important research at the NCI, and for the enduring benefit of cancer patients." 

"The data NCI generates for the entire cancer research community across the nation supports the mission to advance scientific knowledge and help all people live longer, healthier lives," shared Dr. Ginger Zhou, vice president of genomics services at GENEWIZ. "We are honored to become an integral part of this initiative."

GENEWIZ will generate data from DNA samples received from the Biospecimen Core Resource and send raw sequencing data, associated metadata, and other characterization data to the Genomic Data Commons. This data will then be shared with the Genomic Data Analysis Network and research community.

The Center for Cancer Genomics coordinates research teams across the United States and Canada to produce rich cancer genomic and clinical datasets for the cancer research community. They implement these collective efforts through a standardized workflow called the Genome Characterization Pipeline. Components of this pipeline include tissue collecting and processing, genome characterization, genomic data analysis, as well as data sharing and discovery.

About Brooks Automation
Brooks (Nasdaq: BRKS) is a leading provider of life science sample-based solutions and semiconductor manufacturing solutions worldwide. The Company's Life Sciences business provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Brooks Life Sciences' GENEWIZ division is a leading provider of gene sequencing and gene synthesis services. With over 40 years as a partner to the semiconductor manufacturing industry, Brooks is a provider of industry-leading precision vacuum robotics, integrated automation systems and contamination control solutions to the world's leading semiconductor chip makers and equipment manufacturers. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, visit www.brooks.com.

BROOKS INVESTOR CONTACT:
Sherry Dinsmore
Brooks Automation
978.262.4301
sherry.dinsmore@brooks.com

John Mills
Managing Partner
ICR, LLC
646.277.1254
john.mills@icrinc.com

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/brooks-announces-genewiz-selected-as-genome-characterization-center-by-the-national-cancer-institute-301206883.html

SOURCE Brooks Automation

FAQ

What contract was awarded to Brooks Automation's GENEWIZ division by the NCI?

GENEWIZ was awarded a three-year IDIQ contract to provide whole exome sequencing to the National Cancer Institute's Center for Cancer Genomics.

How long is the contract between GENEWIZ and the National Cancer Institute?

The contract is for a period of three years.

What is the significance of the contract awarded to GENEWIZ by the NCI?

The contract enhances GENEWIZ's reputation in the cancer research community and contributes to important cancer genomic research.

Which company has been selected as a Genome Characterization Center by the NCI?

Brooks Automation's GENEWIZ division has been selected as one of the Genome Characterization Centers by the National Cancer Institute.

What services will GENEWIZ provide under the NCI contract?

GENEWIZ will provide whole exome sequencing and generate data from DNA samples to support cancer research.